Claims for Patent: 8,841,125

Summary for Patent: 8,841,125

Title:	Cancer tissue-derived cell mass and a process for preparing same
Abstract:	Disclosed is a novel cell mass derived from a cancer tissue, which can reflect the in vivo behavior of a cancer cell correctly. Also disclosed is a process for preparing the cell mass. Specifically disclosed is a cell mass derived from a cancer tissue, which is an separated product that is isolated from a cancer tissue obtained from an individual as a mass containing at least three cancer cells or a cultured product of the separated product and which can retain a proliferation ability in vitro. The cell mass derived from a cancer tissue is produced by, for example, a preparation process comprising the steps of: treating a pulverized product of a cancer tissue removed from a living body with an enzyme; and selecting and collecting a mass containing at least three cancer cells among from an enzymatic treatment product.
Inventor(s):	Inoue; Masahiro (Osaka, JP), Ohue; Masayuki (Osaka, JP)
Assignee:	Renaissance Energy Investment Co., Ltd. (Hyogo, JP) Osaka Prefectural Hospital Organization (Osaka, JP)
Application Number:	14/231,278
Patent Claims:	1. A process for preparing a cancer tissue-derived cell mass comprising the steps of: treating, with a collagenase-containing enzyme, a pulverized product of a cancer tissue removed from a living body; selecting and collecting a mass containing at least three cancer cells having a diameter or a long diameter of 20 .mu.m to 500 .mu.m or volume average particle size of 20 .mu.m to 500 .mu.m from the enzymatically treated product with a process for assorting the size; and culturing the collected mass to obtain a cultured product that takes an almost spherical or ellipsoidal form. 2. The process for preparing a cancer tissue-derived cell mass according to claim 1, wherein the cultured product that takes an almost spherical or ellipsoidal form consists of cells, 99.54% or more of which express EpCAM. 3. The process for preparing a cancer tissue-derived cell mass according to claim 1, wherein the process for assorting the size is done with the use of a sieve. 4. The process for preparing a cancer tissue-derived cell mass according to claim 1, wherein the step of selecting and collecting a mass containing at least three cancer cells is a step of collecting and selecting an oversized component using a sieve with a mesh size of 40 .mu.m and collecting and selecting an undersized component using a sieve with a mesh size of 250 .mu.m. 5. The process for preparing a cancer tissue-derived cell mass according to claim 1, wherein the enzyme is a mixed enzyme comprising at least one protease selected from the group consisting of C. histolyticum neutral protease, thermolysin, and dispase; and at least one collagenase selected from the group consisting of collagenase I, collagenase II, and collagenase IV. 6. The process for preparing a cancer tissue-derived cell mass according to claim 1, wherein the pulverized product is in the size of about 2 mm cube. 7. The process for preparing a cancer tissue-derived cell mass according to claim 1, wherein the collagenase-containing enzyme treatment is conducted for 30 to 150 minutes, at the temperature of 25 to 39.degree. C. under the conditions of pH 6.about.8. 8. The process for preparing a cancer tissue-derived cell mass according to claim 1, wherein the step for culturing is done in a serum-free media which contains EGF or bFGF in the concentration of 10 to 30% w/v based on the whole medium at least three hours. 9. The process for preparing a cancer tissue-derived cell mass according to claim 1, further comprising the step for mechanically dividing the cultured product that takes an almost spherical or ellipsoidal form. 10. The process for preparing a cancer tissue-derived cell mass according to claim 1, wherein the step of selecting and collecting a mass containing at least three cancer cells is a step of collecting and selecting an oversized component using a sieve with a mesh size of 40 .mu.m and collecting and selecting an undersized component using a sieve with a mesh size of 250 .mu.m with the use of a pipette.

Details for Patent 8,841,125

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2029-03-02